In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii

International Journal of Antimicrobial Agents

Volumn 35, Issue 6, 2010, Pages 550-552

  Li, Houmin ^a   Lu, Qiaoyun ^b   Wan, Zhe ^b   Zhang, Jianzhong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antifungal susceptibility; Drug interaction; Trichosporon asahii

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TRICHOSPORON ASAHII; TRICHOSPORONOSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG SYNERGISM; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PYRIMIDINES; TRIAZOLES; TRICHOSPORON;

EID: 77951767468     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.01.013     Document Type: Article

References (13)

1. Walsh T.J., Groll A.H. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999, 1:247-261.
2. Walsh T.J., Groll A., Hiemenz J., Fleming R., Roilides E., Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004, 10(Suppl. 1):48-66.
3. Tokimatsu I., Karashima R., Yamagata E., Yamakami Y., Nagai H., Kadota J., et al. Pathogenesis of Trichosporon asahii and strategies for infectious control of disseminated trichosporosis. Nippon Ishinkin Gakkai Zasshi 2003, 44:181-186. [in Japanese].
4. Cawley M.J., Braxton G.R., Haith L.R., Reilly K.J., Guilday R.E., Patton M.L. Trichosporon beigelii infection: experience in a regional burn center. Burns 2000, 26:483-486.
5. Ebright J.R., Fairfax M.R., Vazquez J.A. Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. Clin Infect Dis 2001, 33:E28-30.
6. Groll A.H., Walsh T.J. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001, 7(Suppl. 2):8-24.
7. Moretti-Branchini M.L., Fukushima K., Schreiber A.Z., Nishimura K., Papaiordanou P.M., Trabasso P., et al. Trichosporon species infection in bone marrow transplanted patients. Diagn Microbiol Infect Dis 2001, 39:161-164.
8. Walsh T.J., Melcher G.P., Rinaldi M.G., Lecciones J., McGough D.A., Kelly P., et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990, 28:1616-1622.
9. Kamberi P., Atsuro H., Takayoshi T., Masaru N. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice. Chemotherapy 1998, 44:55-62.
10. Serena C., Mariné M., Pastor F.J., Nolard N., Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 2005, 55:1020-1023.
11. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 2nd ed. Document M27-A2. Wayne, PA: CLSI; 2002.
12. Serena C., Pastor F.J., Gilgado F., Mayayo E., Guarro J. Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother 2005, 49:497-502.
13. Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.